Abstract 15415: TEMPO: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of Eleclazine on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Authors

Sergio Cossu MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

6-2018

Volume

136

Issue

1

Published In/Presented At

https://www.ahajournals.org/doi/10.1161/circ.136.suppl_1.15415

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Cardiology Division

Document Type

Article